6 results
To assess the objective response rate (ORR), progression free survival (PFS), overall survival (OS), duration of response (DoR), toxicity, and quality of life (QoL) of patients with advanced SGC treated with cabozantinib in 3 cohorts: salivary duct…
To demonstrate that a dose reduction of 20-33% of CYP3A4 metabolized tyrosine kinase inhibitors in patients expressing the CYP3A4*22 gene (rs35599367 C>T in intron 6) does not result in a lower exposure (Ctrough) than the wildtype group with…
Primary Objective* To explore the pharmacodynamics of ICVT comprised of digoxin and furosemide (dual agent), digoxin (single agent), furosemide (single agent) in patients with AK. * To evaluate clinical efficacy of ICVT comprised of digoxin and…
Primary Objective:- Demonstrate the efficacy of ozanimod compared to placebo on the maintenance of clinical remission and endoscopic responseSecondary Objectives:- Demonstrate the efficacy of ozanimod compared to placebo on maintenance of clinical…
The objective of this study is to demonstrate the long-term safety and explore tong-term efficacy of ozanimod for the treatment of subjects with moderately to severely active CD.
Primary objective:- Demonstrate the efficacy of ozanimod compared to placebo on the induction of clinical remissionSecondary objectives:- Demonstrate the efficacy of ozanimod compared to placebo on induction of clinical response, clinical remission…